{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:37:10Z","timestamp":1773873430837,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP 1145952"],"award-info":[{"award-number":["OPP 1145952"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.biologicals.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T00:33:22Z","timestamp":1536366802000},"page":"29-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG"],"prefix":"10.1016","volume":"56","author":[{"given":"Sjoerd","family":"Rijpkema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Hockley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rigsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celina","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Goldblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Novilia S.","family":"Bachtiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesan","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2018.09.001_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(00)44360-6","article-title":"A new antigen of B. typhosus. Its relation to virulence and to active and passive immunisation","volume":"227","author":"Felix","year":"1934","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2018.09.001_bib2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/infdis\/150.3.436","article-title":"Re-examination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi","volume":"150","author":"Robbins","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biologicals.2018.09.001_bib3","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.biologicals.2018.09.001_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0264-410X(94)90194-5","article-title":"Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines","volume":"12","author":"Keitel","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2018.09.001_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/INF.0b013e31812565bc","article-title":"Revaccination with locally-produced vi typhoid polysaccharide vaccine among Chinese school-aged children: safety and immunogenicity findings","volume":"26","author":"Zhou","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.biologicals.2018.09.001_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.biologicals.2018.09.001_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006454-199102000-00004","article-title":"Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California kaiser permanente vaccine study center pediatrics group","volume":"10","author":"Black","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.biologicals.2018.09.001_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00006454-199102000-00003","article-title":"Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California kaiser permanente vaccine study center pediatrics group","volume":"10","author":"Black","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.biologicals.2018.09.001_bib9","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1128\/IAI.67.11.5806-5810.1999","article-title":"Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"67","author":"Kossaczka","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.biologicals.2018.09.001_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five- year-old Children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biologicals.2018.09.001_bib11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/CVI.00532-10","article-title":"The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines","volume":"18","author":"Thiem","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.biologicals.2018.09.001_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biologicals.2018.09.001_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/21645515.2015.1117715","article-title":"Efficacy and safety of Vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph\u2122) in Indian children: school based cluster randomized study","volume":"12","author":"Mitra","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.biologicals.2018.09.001_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biologicals.2003.09.002","article-title":"Detection of O-acetylated Vi polysaccharide of Salmonella enterica subspecies typhi by enzyme immunoassay","volume":"32","author":"Rijpkema","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2018.09.001_bib15","series-title":"A WHO collaborative study to evaluate a candidate International Standard for anti-Typhoid capsular Vi polysaccharide IgG (Human)","author":"Rijpkema","year":"2014"},{"key":"10.1016\/j.biologicals.2018.09.001_bib16","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1016\/j.vaccine.2013.07.070","article-title":"Working Group on quality, safety and efficacy of typhoid Vi capsular polysaccharide conjugate vaccines, Jeju, Republic of Korea, 5-7 September 2012","volume":"31","author":"Jones","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2018.09.001_bib17","series-title":"WHO Guidelines on the quality, safety and efficacy of typhoid conjugate vaccines. 64th Meeting of the WHO Expert Committee on Biological Standardization","first-page":"21","author":"WHO","year":"2013"},{"key":"10.1016\/j.biologicals.2018.09.001_bib18","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.vaccine.2013.02.006","article-title":"A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned","volume":"31","author":"Szu","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2018.09.001_bib19","first-page":"82","article-title":"Proposed first WHO international standard for anti-Vi polysaccharide serum (human). 66th meeting of the WHO Expert Committee on Biological Standardization, 12 to 16 October 2015","volume":"999","author":"WHO","year":"2016","journal-title":"WHO Tech Rep Ser"},{"key":"10.1016\/j.biologicals.2018.09.001_bib20","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1128\/JCM.25.12.2266-2269.1987","article-title":"Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers","volume":"25","author":"Losonsky","year":"1987","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.biologicals.2018.09.001_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0022-1759(88)90317-1","article-title":"Measurement of anti-Haemophilus influenzae type b capsular polysaccharide antibodies by ELISA","volume":"115","author":"Barra","year":"1988","journal-title":"J Immunol Meth"},{"key":"10.1016\/j.biologicals.2018.09.001_bib22","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1128\/IAI.59.12.4349-4356.1991","article-title":"Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C Meningococcal polysaccharides in sera from vaccinees and carriers","volume":"59","author":"Arakere","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.biologicals.2018.09.001_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2249.2004.02439.x","article-title":"Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors","volume":"136","author":"Ferry","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.biologicals.2018.09.001_bib24","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"6736","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2018.09.001_bib25","first-page":"73","article-title":"WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004). 55th Meeting of the WHO Expert Committee on Biological Standardization, 15 to 18 November 2004","volume":"932","author":"WHO","year":"2006","journal-title":"WHO Tech Rep Ser"},{"key":"10.1016\/j.biologicals.2018.09.001_bib26","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.vaccine.2018.05.038","article-title":"Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: phase I trial in Healthy Filipino adults and children","volume":"36","author":"Capeding","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2018.09.001_bib27","unstructured":"EDQM \u2013 Council of Europe. CombiStats v5.0. www.combistats.eu."},{"key":"10.1016\/j.biologicals.2018.09.001_bib28","first-page":"72","article-title":"First WHO international standard for anti-typhoid capsular Vi polysaccharide immunoglobulin G (human). 68th meeting of the WHO Expert Committee on Biological Standardization, 12 to 16 October 2017","volume":"1011","author":"WHO","year":"2018","journal-title":"WHO Tech Rep Ser"},{"key":"10.1016\/j.biologicals.2018.09.001_bib29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2307\/2529472","article-title":"Predicting the stability of biological standards and products","volume":"33","author":"Kirkwood","year":"1977","journal-title":"Biometrics"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105618302835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105618302835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T06:37:18Z","timestamp":1604903838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105618302835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":29,"alternative-id":["S1045105618302835"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2018.09.001","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd on behalf of International Alliance for Biological Standardization.","name":"copyright","label":"Copyright"}]}}